Appleton Partners Inc. MA raised its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 8.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 18,038 shares of the medical research company’s stock after purchasing an additional 1,478 shares during the quarter. Appleton Partners Inc. MA’s holdings in Amgen were worth $3,137,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in AMGN. Baker Ellis Asset Management LLC bought a new stake in shares of Amgen in the third quarter worth approximately $108,000. Jackson Grant Investment Advisers Inc. grew its stake in shares of Amgen by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after acquiring an additional 5 shares during the period. Phocas Financial Corp. bought a new stake in shares of Amgen in the second quarter worth approximately $110,000. Omnia Family Wealth LLC grew its stake in shares of Amgen by 25.3% in the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after acquiring an additional 147 shares during the period. Finally, Salem Investment Counselors Inc. grew its stake in shares of Amgen by 4.7% in the second quarter. Salem Investment Counselors Inc. now owns 809 shares of the medical research company’s stock worth $139,000 after acquiring an additional 36 shares during the period. Institutional investors and hedge funds own 78.95% of the company’s stock.
Amgen, Inc. (NASDAQ AMGN) opened at $183.55 on Friday. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35. Amgen, Inc. has a 1-year low of $152.16 and a 1-year high of $201.23. The firm has a market cap of $133,200.00, a P/E ratio of 16.69, a price-to-earnings-growth ratio of 2.26 and a beta of 1.42.
Amgen declared that its Board of Directors has authorized a stock repurchase plan on Wednesday, October 25th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be issued a dividend of $1.32 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $5.28 annualized dividend and a yield of 2.88%. This is an increase from Amgen’s previous quarterly dividend of $1.15. Amgen’s payout ratio is currently 48.00%.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $176.83, for a total transaction of $269,665.75. Following the transaction, the executive vice president now owns 56,106 shares of the company’s stock, valued at $9,921,223.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 4,575 shares of company stock worth $818,361 in the last ninety days. Insiders own 0.19% of the company’s stock.
AMGN has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $199.00 price target for the company in a research note on Friday, October 27th. Citigroup lowered shares of Amgen to a “neutral” rating in a research note on Monday, December 18th. Royal Bank of Canada reduced their price target on shares of Amgen from $192.00 to $188.00 and set a “sector perform” rating for the company in a research note on Thursday, October 26th. Goldman Sachs Group lowered shares of Amgen from a “conviction-buy” rating to a “buy” rating in a research note on Friday, December 15th. Finally, Mizuho set a $198.00 price objective on shares of Amgen and gave the stock a “buy” rating in a report on Sunday, October 29th. Sixteen investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Amgen currently has an average rating of “Hold” and an average target price of $191.84.
COPYRIGHT VIOLATION NOTICE: “Appleton Partners Inc. MA Has $3.14 Million Holdings in Amgen, Inc. (AMGN)” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2018/02/18/appleton-partners-inc-ma-has-3-14-million-holdings-in-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.